Short Interest in Dominari Holdings Inc. (NASDAQ:DOMH) Drops By 57.7%

Dominari Holdings Inc. (NASDAQ:DOMHGet Free Report) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 5,800 shares, a drop of 57.7% from the January 15th total of 13,700 shares. Based on an average daily volume of 12,000 shares, the short-interest ratio is currently 0.5 days. Approximately 0.2% of the shares of the company are short sold.

Insider Transactions at Dominari

In other Dominari news, CEO Anthony Hayes bought 70,000 shares of Dominari stock in a transaction dated Wednesday, December 20th. The stock was purchased at an average price of $2.00 per share, for a total transaction of $140,000.00. Following the completion of the purchase, the chief executive officer now directly owns 98,804 shares of the company’s stock, valued at $197,608. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders acquired 95,804 shares of company stock worth $201,824 over the last quarter. Corporate insiders own 9.74% of the company’s stock.

Hedge Funds Weigh In On Dominari

A number of large investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Dominari in the second quarter valued at approximately $219,000. Geode Capital Management LLC bought a new position in shares of Dominari in the second quarter valued at approximately $126,000. Renaissance Technologies LLC purchased a new stake in Dominari in the second quarter valued at approximately $109,000. State Street Corp bought a new stake in Dominari during the second quarter valued at approximately $58,000. Finally, Citadel Advisors LLC purchased a new position in Dominari in the 2nd quarter worth approximately $52,000. 11.90% of the stock is currently owned by institutional investors.

Dominari Price Performance

Shares of DOMH stock traded up $0.10 during trading hours on Monday, reaching $2.31. The stock had a trading volume of 19,804 shares, compared to its average volume of 9,638. The stock’s fifty day simple moving average is $2.28 and its 200 day simple moving average is $2.38. Dominari has a 12 month low of $1.76 and a 12 month high of $4.45.

About Dominari

(Get Free Report)

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.

Read More

Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.